| |
 |
Kraig
Biocraft Laboratories, Inc. (OTCBB: KBLB)
|
 |
**Breaking News**
Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB) announced today
the renewal and expansion of its Collaborative Research and Intellectual
Property Agreement with the University of Notre
Dame.
Please take a moment to review the two NEWS Releases below
<<<Spacer>>>
|
Breaking *NEWS*
From Kraig Biocraft Labs |
|
Press Release Source:
Kraig Biocraft Laboratories, Inc.
Thursday May 8,
6:00 am ET
Kraig Biocraft Laboratories, Inc.
Signs Intellectual Property and Collaborative Research Agreement With the
University of Notre Dame
Expansion of Kraig's Sponsored Research
Within University Laboratories to Include Development of Technical Textiles,
Diagnostics and Platform Technologies
LANSING, Mich., May
8, 2008 (PRIME NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTC BB:KBLB.OB
- News) announced this morning that the Company has just signed a renewal
and expansion of its Collaborative Research and Intellectual Property Agreement
with the University of Notre Dame. The agreement provides Kraig with exclusive
licensing rights for the products and technology developed pursuant to
the collaboration. Additionally, the agreement extends and expands the
Company's ongoing research and development program in the University's
genetic laboratories.
"The sponsored research
program with the University of Notre Dame is a continuing success,'' said
Kraig's CEO Kim Thompson, "and has already resulted in two provisional
patent filings. Kraig's renewal extends the collaborative research into
2009, and expands the focus of the Company's work to include the development
of genetic expression systems. These recombinant DNA technologies have
potential applications as pharmaceutical platforms and human diagnostics
platforms. Each genetic expression system provides multiple possibilities
for highly lucrative opportunities for the Company's technology."
The Company's primary
focus will remain on the development of high performance, high tensile
strength fibers for the multi-billion dollar technical textile market.
However, the collaborative research agreement and university research plan
will open up new opportunities for Kraig to develop pharmaceutical and
diagnostic applications for its genetic engineering technology. This work
will continue in the University under the direction of Dr. Malcolm Fraser,
a renowned developer of genetic engineering technologies and a member of
Kraig's board of scientific advisors.
Already in 2008, Kraig
has been able to announce the filing of a provisional patent application
for human diagnostic technologies. The invention was a byproduct of the
Company's collaborative research program with the University. ``The new
research plan announced today is an acknowledgement by the Company that
this technology has broad applications as a platform technology. These
platforms can potentially service multiple markets including human and
animal diagnostics, pharmaceutical platforms and recombinant polymers,''
said Thompson.
A second provisional
patent application was filed by the University earlier this year regarding
new gene splicing and genetic engineering technologies. The invention relates
to the use of DNA's natural repair mechanisms to facilitate gene splicing.
This patent application was also filed pursuant to Kraig's collaborative
research agreement.
``We are elated that
the successful and productive research and development program with the
University of Notre Dame will continue into 2009,'' said Thompson. ``With
the new and expanded research plan now in place, we look forward to a fruitful
year. Kraig is truly a proud sponsor of scientific research and technological
development within the University of Notre Dame. We want to thank the University
for this renewal of our agreement, and for the diligent work of the scientists
who are helping Kraig to make the future in pharmaceutical and textile
technologies.''
Kraig Biocraft Laboratories
is a technology company focused on the development of commercially significant
high-performance polymers, technical fibers and diverse platform technologies.
Based on proprietary genetic engineering technology, Kraig is working to
develop and produce polymers and protein-based materials including Spider
Silk.
For more information
on Kraig Biocraft Laboratories please visit the Company's web site: http://www.KraigLabs.com
An audio interview discussing
corporate developments is also available on the website.
The Kraig Biocraft Laboratories,
Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=4817
Statements in this press
release about the Company's future and expectations other than historical
facts are ``forward-looking statements.'' These statements are made on
the basis of management's current views and assumptions. As a result, there
can be no assurance that management's expectations will necessarily come
to pass. These forward-looking statements generally can be identified by
phrases such as ``believes,'' ``plans,'' ``expects,'' ``anticipates,''
``efforts,'' ``foresees,'' ``future'', ``forecasts,'' ``estimates'', ``intends,''
``develop,'' ``researching,'' ``research,'' ``goal,'' ``opportunities,''
``potential,'' ``possibility,'' ``pursue,'' ``could'', ``should'' or other
words or phrases of similar import. Similarly, statements in this release
that describe the Company's business strategy, outlook, objectives, plans,
intentions, marketing strategies, ongoing research, or goals should all
be considered forward-looking statements. All such forward-looking statements
are subject to certain risks and uncertainties that could cause actual
results to differ materially from those in forward-looking statements.
Management cautions that its ability to further its research, and create
commercially-viable products and execute on its marketing plans may be
affected by the competitive environment, the Company's financial condition
and its ability to raise sufficient capital to meet the financial obligations
of its business plan and to fund its continuing operations.
Contact:
Kraig Biocraft Laboratories, Inc.
Kim Thompson, CEO
(517) 336-0807
info@KraigLabs.com
Source: Kraig Biocraft
Laboratories, Inc.
<<<spacer>>><<<Spacer>>>
|
About Kraig Biocraft Labs |
|
Kraig Biocraft Laboratories, Inc. ("Kraig""KBLB") is a biotechnology company focused on the development of commercially significant
high performance polymers and technical fiber. Based on proprietary genetic
engineering technology, Kraig is working to develop and produce polymers
and protein-based materials including Spider Silk. The company believes
that Spider Silk is a “super fiber” that will have numerous commercial
and consumer applications.
Applications of High Performance Fibers
High performance technical fibers are currently
used in a wide variety of military, industrial, and consumer applications
requiring superior strength, toughness and flexibility. Kraig investments
in genetic research are focused on product development and innovative near
term solutions to meet the practical problems of our world. Kraig is sponsoring
genetic research at laboratories within the University
of Notre Dame to create new polymers for
the broad commercial markets that have been waiting for the next evolution
of materials. Kraig has also been working with leading universities in
the fields of genetics and genetic engineering to develop new varieties
of recombinant fibers including spider silks and spider silk analogs.
Kraig has obtained the exclusive right, in its field of research, for
the spider silk gene sequences which are at the core of its technology.
These genetic sequences were first studied and subsequently patented by Dr.
Randy Lewis of the University of Wyoming (Dr. Lewis is a KBLB scientific
adviser). In early 2006, Kraig obtained certain exclusive rights
from the University of Wyoming to utilize the spider silk DNA sequences
in its field of use.
Genetic Engineering is the means by which KBLB can manipulate DNA
to modify and create new biochemical products. At Kraig, the trademark
saying is "The future is made
in the laboratory" and that's more than a slogan. It
is the company's future, and that of the next generation of materials science
that KBLB is making with those genetic sequences. Management at KBLB is
focused on the development of high strength materials and industrial polymers
by working through collaborative research and licensing agreements in the
field of genetics, with leading university laboratories.
<<<spacer>>>
|
What's So Special About Spider Silk? |
|
It
is five times as strong as steel, twice as elastic as polyamide fibers
(it
can be stretched by 31% without breaking),
it
is more elastic than aramid fiber,
it
is finer than a human hair,
and
lighter than cotton.
Life
Science and Genetic Technology
Spider Silk is among the strongest fibers produced in nature. Some spider species are capable of producing up to seven different types
of silk depending upon the spider's particular need at that time. For example,
a spider will use one type of silk to make the structural supports for
it web, and another type to wrap its captured pray. Drag line silk, the
silk used when a spider is repelling, is of particular commercial interest.
This natural polymer is both extremely strong and extremely flexible.
However, spider silk is much less dense than
steel; its tensile strength to density ratio is roughly five times
higher than that of steel (i.e. it is five times as strong as steel of
the same density — as strong as Aramid filaments, such as Twaron or Kevlar.)
In fact, a strand of spider silk long enough to circle the earth would
weigh less than 16 ounces (450 g).
- Dragline silk: Used
for the web's outer rim and spokes, as well as for the lifeline. As strong
as steel, but much tougher.
- Capture-spiral silk:
Used for the capturing lines of the web. Sticky, extremely stretchy and
tough.
- Tubiliform silk:
Used for protective egg sacs. Stiffest silk.
- Aciniform silk: Used
to wrap and secure freshly captured prey. Two to three times as tough as
the other silks.
- Minor-ampullate silk:
Used for minor, all-purpose applications.
HOW
THEY DO IT
Depending on the species, spiders will have anything
from two to eight spinnerets, usually in pairs. The beginning of the gland
is rich in thiol and tyrosine groups. After this beginning process, the
ampulla acts as a storage sac for the newly created fibers. From there,
the spinning duct effectively removes water from the fiber and through
fine channels also assists in its formation. Lipid secretions take place
just at the end of the distal limb of the duct, and proceeds to the valve.
The valve is believed to assist in rejoining broken fibers, acting much
in the way of a helical pump.
Unspun silk dope is pulled through silk glands,
resulting in a transition from stored gel to final solid fiber. Many species
of spider have different glands for different jobs, such as housing and
web construction, defense, capturing and detaining prey, mobility and in
extreme cases even as food. Thus, different specialized silks have evolved
with material properties optimized for their intended use.
a
|
The Market and the Applications |
|
a
| The DNA research that has been conducted in laboratories
around the world over the last 20 years, has paved the way for new products
and opened up commercial opportunities that would have been undreamed of
a generation ago.
DNA instructs cells in their life processes. Genetic
engineering is the means by which that machinery is employed. |
Artist Kebes using vector
drawing software Structure of spider silk. Inside a typical fiber, one
finds crystalline regions separated by amorphous linkages. The crystals
are beta-sheets that have assembled together.
|
Transgenics is the scientific process of decoding
the genetic instructions of an organism and applying those instructions
to another organism. In that way, bio chemicals and other products can
be produced and delivered on an industrial scale.
KBLB is at the forefront
of the coming revolution in materials technology. |
MODERN APPLICATIONS
Genetic Engineering, is the key to a brighter future for
both consumers and industry.
BIOENGINEERED SPIDER SILKS
HAVE TREMENDOUS POTENTIAL IN THE MARKET PLACE FOR HIGH STRENGTH, LIGHT-WEIGHT
MATERIALS SUCH AS:
Bulletproof vests, parachute
cords, suspension cables, wear-resistant shoes
and clothing, seat belts, rust-free
bumpers for automobiles,
artificial tendons and ligaments
Scientists
have previously suggested that a mere pencil-thick strand of silk
could actually stop a Boeing
747 in mid flight.
As with all things having to do with thin reinforced
materials,
the U.S. military has in the past expressed great
interest in spider silks. In fact, the U.S. Army funded research into production
methods for spider silk, but was unable to replicate the mechanical properties
of the fiber as produced in nature. But interest in the new material doesn't
stop there. Clothing and fabric companies could also benefit from the discovery
as well as medical companies that make stents and other biomedical devices.
|
Other Recent News From KBLB |
|
Press Release Source:
Kraig Biocraft Laboratories, Inc.
Thursday April
10, 6:00 am ET
Kraig Biocraft Laboratories, Inc.
Announces Patent Filing On Human Diagnostics Technology
New Diagnostics Platform Incorporating
Antigen Fused Polymers
LANSING, Mich., April
10, 2008 (PRIME NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTC BB:KBLB.OB
- News) announced today that a provisional patent application describing
a platform for antigen presentation and antibody test kits has been filed
listing Dr. Malcolm Fraser, a member of Kraig's Scientific Advisory Board,
as the named inventor.
The patent application
was filed earlier this year by the University of Notre Dame, where Dr.
Fraser heads the University's Laboratory of Molecular Virology.
``The invention describes
engineered polymers which incorporate diagnostic antigens,'' explained
Dr. Malcolm Fraser. ``The genetically fused polymers can potentially be
fashioned into a number of different diagnostic test platforms including
serum (blood), salivary, and urine based diagnostics. One of the advantages
of a polymer based diagnostic platform is its ability to incorporate multiple
antigens into a final product simply by weaving the polymers,'' Fraser
continued. ``The result would be a diagnostic tool which could simultaneously
screen for several diseases or for other important parameters.''
This is the second patent
application of 2008 which was made pursuant to Kraig's sponsored research
program at the University of Notre Dame and which is subject to Kraig's
intellectual property agreement with the University. That agreement provides
for exclusive licensing rights for Kraig sponsored research. It is the
first such patent application made pursuant to that program relating to
human health.
``This ground breaking
technology advances Kraig into the growing field of human and animal diagnostics,''
said company CEO Kim Thompson. ``The tremendous potential of genetically
fused polymers for diagnostics can not be ignored,'' continued Thompson.
``Our announcement is a big step toward fulfilling the promise of genetically
engineered fibers for diagnostics and human health.'' MORE
Press Release Source:
Kraig Biocraft Laboratories, Inc.
Monday April 7,
6:00 am ET
Kraig Biocraft Laboratories, Inc.
Announces Patent Filing On Genetic Engineering and Gene Splicing Technology
System for Producing Radically New
Fibers and Textiles
LANSING, Mich., April
7, 2008 (PRIME NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTC BB:KBLB.OB
- News) announced today that Dr. Malcolm Fraser, a scientific consultant
to Kraig, and a member of its Scientific Advisory Board, is the named inventor
in a now pending provisional patent application describing a system and
methodology for redirecting a cell's natural DNA repair processes to perform
site-directed cleavage and targeted genetic insertion. The patent describes
applications for producing genetically engineered silk fibers. The patent
was filed earlier this year by the University of Notre Dame, where Dr.
Fraser heads the University's Laboratory of Molecular Virology.
``This genetic engineering
system for site-directed cleavage and insertion takes advantage of the
DNA's own repair mechanism to insert our own genetic instructions,'' said
Dr. Fraser. ``In one of the most important aspects of the invention, it
would be possible to insert genetic instructions for the production of
polymers with different properties including elasticity and tensile strength.''
``Such polymers could
provide radically new fibers and textiles for a number of industries, including
human health applications,'' continued Fraser.
The patent application
was made pursuant to Kraig's sponsored research program at the University
of Notre Dame and is subject to Kraig's intellectual property agreement
with the University. That agreement provides for exclusive licensing rights
for Kraig sponsored research. MORE
Press Release Source:
Kraig Biocraft Laboratories, Inc.
Tuesday March
18, 6:00 am ET
Kraig Biocraft Laboratories, Inc.
Announces Patent Filing On a New Molecule and
the Artificial DNA Sequences for
Producing the Same
New Composites Designed for High-Performance
Fiber Market
LANSING, Mich., March
18, 2008 (PRIME NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTC BB:KBLB.OB
- News) announced today that it has filed a provisional patent application
describing the invention of a number of protein molecules. Also claimed
in the application are the artificial DNA sequences which code for these
polymers. The application, filed with the U.S. Patent and Trade Mark office
in late February, additionally claims a large number of composite fibers
which incorporate one or more of the artificial protein molecules.
"These polymers were
specifically designed for use as the primary constituents of high performance
fibers. Our goal is to create new composites for use in the rapidly growing
technical fibers market,'' said Kim Thompson, Kraig's CEO.
The market for technical
fibers was estimated at $92.8 billion in 2007. It is projected to grow
to $127 billion by 2010 (an average of 10% growth per year).
"These new polymers and
composites were inspired by our continuing work with spider silk DNA,"
continued Thompson. "What is exciting for the technical fibers industry
is the tremendous potential of these polymers to satisfy the growing need
for new materials with high strength to weight ratios. We believe that
the technology disclosed in our patent application will create the foundation
for further advances in the high performance fibers marketplace."
Copies of KBLB's latest
financial reports and SEC filings are available on the EDGAR system and
on the Company's web site: http://www.KraigLabs.com
The Kraig Biocraft Laboratories,
Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=4817
Statements in this press
release about the company's future and expectations other than historical
facts are ``forward-looking statements.'' These statements are made on
the basis of management's current views and assumptions. As a result, there
can be no assurance that management's expectations will necessarily come
to pass. These forward-looking statements generally can be identified by
phrases such as ``believes,'' ``plans,'' ``expects,'' ``anticipates,''
``foresees,'' ``forecasts,'' ``estimates'', ``develops'', ``researching'''
``research,'' ``goal,'' ``potential'' or other words or phrases of similar
import. Similarly, statements in this release that describe the Company's
business strategy, outlook, objectives, plans, intentions or goals should
all be considered forward-looking statements. All such forward-looking
statements are subject to certain risks and uncertainties that could cause
actual results to differ materially from those in forward-looking statements.
Management cautions that its ability to further its research, and create
commercially-viable products may be affected by the competitive environment,
the Company's financial condition and its ability to raise sufficient capital
to meet the financial obligations of its business plan and to fund its
continuing operations.
Contact:
Kraig Biocraft Laboratories, Inc.
Kim Thompson, CEO
(517) 336-0807
info@KraigLabs.com
Source: Kraig Biocraft
Laboratories, Inc.
aa
|
Financial Information for KBLB |
|
Sector: Basic Materials
Industry: Synthetics
Recent Price: 0.37
Estimated Market Cap: 18.53M
Shares Outstanding: 49.93M
For a PDF viewable in AdobeReader of the KBLB 10Qsb Report for the period ended 09/30/07, Click
Here
For the latest FREE version of Adobe Reader, click on
the logo below to be redirected to the Adobe site.
KBLB has no off-balance sheet
arrangements. KBLB nor any of its subsidiaries
is a party to any pending or
threatened legal proceedings.
Kraig Biocraft Laboratories,
Inc. is represented by the law firm of: Anslow & Jaclin, LLP, 195 Route
9 South, Suite 204, Manalapan , NJ 07726.
KBLB auditors are: Webb
& Company, P.A., 1501 Corporate Drive, Suite 150, Boynton Beach , FL
33426.
The KBLB transfer agent:
Registrar & Transfer Company, 10 Commerce Drive, Cranford, NJ
07016-3572 - (800) 866-1340.
aa
|
TO CONTACT KBLB |
|
Kraig Biocraft Laboratories, Inc.
Kim Thompson, CEO
120 North Washington Square, Suite 805, Lansing, Michigan
48933
Telephone: (517) 336-0807 - Email: corporate@KraigLabs.com
Web site: www.kraiglabs.com
120 N. Washington Sq.
*** The Bull is Running. ***
There
may never be a better time to feature YOUR company
to
over 1 MILLION investors.
To learn
more about our programs email us directly at info@stockupticks.com
Stockupticks
Safe Harbor Statement: Statements contained in this document,
including those pertaining to estimates and related plans, potential mergers
and acquisitions, estimates, growth, establishing new markets, expansion
into new markets and related plans other than statements of historical
fact, are forward-looking statements subject to a number of uncertainties
that could cause actual results to differ materially from statements made.
Sentences or phrases that use such words as "projection", “projected”,
“attempt”, “intention”, “expect”, “expectation”, “believe”, “anticipates”,
“looking”, “goal”, “target”, “hopeful”, “should”, “pro-forma”, “appears”,
“assumption”, “working on”, “research”, “developing”, “development”, “eventual”,
“approximately”, “potential” and others indicate forward-looking statements,
but their absence does not mean that a statement is not forward-looking.
StockUpTicks.com is a property of Market Pathways Financial Relations Incorporated
(MP). MP provides no assurance as to the subject company's plans
or ability to effect any planned and/or proposed actions. MP has no first-hand
knowledge of management and therefore cannot comment on its capabilities,
intent, resources, nor experience and makes no attempt to do so. Statistical
information, dollar amounts, and market size data was provided by the subject
company and related sources believed by MP to be reliable, but MP provides
no assurance, and none is given, as to the accuracy and completeness of
this information.
Disclaimer: StockUpTicks.com is a property of Market Pathways Financial Relations Incorporated
(MP). The information, opinions and analysis contained herein are
based on third party sources believed to be reliable but no representation,
expressed or implied, is made as to its accuracy, completeness or correctness.
Past performance is no guarantee of future results. This report is a paid
advertisement and is for information purposes only and should not be used
as the basis for any investment decision. MP
has been paid thirty thousand dollars by Kraig Biocraft Laboratories, Inc.
for preparation and distribution of this report and other advertising services
over a ninety day period. This constitutes a conflict of interest
as to MP’s ability to remain objective in its communication regarding the
subject company. Write or call MP for detailed disclosure as required
by Rule 17b of the Securities Act of 1933/1934 - Market Pathways 17595
Harvard Ave., Suite C519 Irvine, CA 92614. MP is not an investment
advisor and this report is not investment advice. This information is neither
a solicitation to buy nor an offer to sell securities but is a paid advertisement.
Information contained herein contains forward-looking statements and is
subject to significant risks and uncertainties, which will affect the results.
The opinions contained herein reflect our current judgment and are subject
to change without notice. MP and/or its affiliates, associates and employees
from time to time may have either a long or short position in securities
mentioned. Information contained herein may not be reproduced in
whole or in part without the express written consent of Market Pathways
Financial Relations Incorporated. |
|
